Sergio Chiarella, MD
Allergy & Immunology · Rochester, MNNPI 1295020550
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,250 of the $1,457 with a category attached, or 85.8%. Merck accounts for 85.8% of it on its own, with 3 other manufacturers making up the rest.
Across 5 payments — averaging $291.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Biocryst US Sales Co., LLC$149
- Novartis$35
- Incyte Corporation$23
Across 5 payments — averaging $12,112 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$46K
- Genentech, Inc.$12K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$1,25086%
- Food & beverage$20714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $1,250 |
| Biocryst US Sales Co., LLC | 1 | $149 |
| Novartis | 1 | $35 |
| Incyte Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orladeyo$149
How this compares
$1,457 in reported general payments places this provider in the 65th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,793 |
| Montelukast Sodium | 21 | $154 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Rochester
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- David LoweRochester$18K
- Dayne VoelkerRochester$8K
- Michael D'nettoRochester$2K
- Caitlin McNultyRochester$966
- Elizabeth EnderRochester$815
- Andrea SitekRochester$427
- Phillip LinkRochester$213
- James LiRochester$134
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.